Glutamate and dopamine in schizophrenia: An update for the 21st century

A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic)

(2014) Oliver D. Howes et al.   BRITISH JOURNAL OF PSYCHIATRY

Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies

(2014) Joseph Kambeitz et al.   BRITISH JOURNAL OF PSYCHIATRY

Schizophrenia: from dopaminergic to glutamatergic interventions

(2014) Marc Laruelle   CURRENT OPINION IN PHARMACOLOGY

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study

(2014) D. Bugarski-Kirola et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Initial Evaluation of 18F-GE-179, a Putative PET Tracer for Activated N-Methyl D-Aspartate Receptors

(2014) C. J. McGinnity et al.   JOURNAL OF NUCLEAR MEDICINE

Biological insights from 108 schizophrenia-associated genetic loci

(2014)   NATURE

Stress-Induced Dopamine Response in Subjects at Clinical High Risk for Schizophrenia with and without Concurrent Cannabis Use

(2014) Romina Mizrahi et al.   NEUROPSYCHOPHARMACOLOGY

Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies

(2014) Sudhakar Selvaraj et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings

(2014) Eline M.P. Poels et al.   SCHIZOPHRENIA RESEARCH

Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial

(2014) Fang Liu et al.   SCHIZOPHRENIA RESEARCH

Dopaminergic basis of salience dysregulation in psychosis

(2014) Toby T. Winton-Brown et al.   TRENDS IN NEUROSCIENCES

Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia

(2014) Juan R. Bustillo et al.   JAMA Psychiatry

Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia

(2013) Arsime Demjaha et al.   AMERICAN JOURNAL OF PSYCHIATRY

Presynaptic Striatal Dopamine Dysfunction in People at Ultra-high Risk for Psychosis: Findings in a Second Cohort

(2013) Alice Egerton et al.   BIOLOGICAL PSYCHIATRY

Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function

(2013) Arsime Demjaha et al.   BIOLOGICAL PSYCHIATRY

Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms

(2013) Michael A.P. Bloomfield et al.   BIOLOGICAL PSYCHIATRY

Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study

(2013) Oliver D. Howes et al.   BRAIN

Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task

(2013) Ivonne Suridjan et al.   JOURNAL OF PSYCHIATRY & NEUROSCIENCE

Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways

(2013) Aline Santos Monte et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010

(2013) Harvey A Whiteford et al.   LANCET

Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study

(2013) R Narendran et al.   MOLECULAR PSYCHIATRY

Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders and associations with SNPs in postmortem brain

(2013) S S Kaalund et al.   MOLECULAR PSYCHIATRY

Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver

(2013) Scott A. Schobel et al.   NEURON

Acute Shift in Glutamate Concentrations Following Experimentally Induced Panic with Cholecystokinin Tetrapeptide—A 3T-MRS Study in Healthy Subjects

(2013) Peter Zwanzger et al.   NEUROPSYCHOPHARMACOLOGY

Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia

(2013) Agata Szulc et al.   NEUROSCIENCE LETTERS

Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users

(2013) James M. Stone et al.   PSYCHOPHARMACOLOGY

Reduced Frontal Glutamate + Glutamine and N-Acetylaspartate Levels in Patients With Chronic Schizophrenia but not in Those at Clinical High Risk for Psychosis or With First-Episode Schizophrenia

(2013) Tatsunobu Natsubori et al.   SCHIZOPHRENIA BULLETIN

Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy

(2013) Neeraj Tandon et al.   SCHIZOPHRENIA RESEARCH

Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium Nitroprusside

(2013) Jaime E. C. Hallak et al.   JAMA Psychiatry

Glutamate Levels in the Associative Striatum Before and After 4 Weeks of Antipsychotic Treatment in First-Episode Psychosis

(2013) Camilo de la Fuente-Sandoval et al.   JAMA Psychiatry

The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment

(2012) Oliver D. Howes et al.   ARCHIVES OF GENERAL PSYCHIATRY

Increased Stress-Induced Dopamine Release in Psychosis

(2012) Romina Mizrahi et al.   BIOLOGICAL PSYCHIATRY

Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients

(2012) Mette Ødegaard Nielsen et al.   BIOLOGICAL PSYCHIATRY

Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation

(2012) Oliver D. Howes et al.   BRITISH JOURNAL OF PSYCHIATRY

Sustained NMDA Receptor Hypofunction Induces Compromised Neural Systems Integration and Schizophrenia-Like Alterations in Functional Brain Networks

(2012) Neil Dawson et al.   CEREBRAL CORTEX

Recent Advances in Targeting the Ionotropic Glutamate Receptors in Treating Schizophrenia

(2012) Robert E. McCullumsmith et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments

(2012) O. D. Howes et al.   CURRENT PHARMACEUTICAL DESIGN

PET and SPECT tracers for glutamate receptors

(2012) Vattoly J. Majo et al.   DRUG DISCOVERY TODAY

Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis

(2012) Oswald J.N. Bloemen et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability

(2012) Ingo Vernaleken et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia

(2012) Mark Weiser et al.   JOURNAL OF CLINICAL PSYCHIATRY

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

(2012) Imran B Chaudhry et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Striatal dopamine release in schizophrenia comorbid with substance dependence

(2012) J L Thompson et al.   MOLECULAR PSYCHIATRY

Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice

(2012) Robert E. Featherstone et al.   NEUROBIOLOGY OF DISEASE

Nature or Nurture? Determining the Heritability of Human Striatal Dopamine Function: an [18F]-DOPA PET Study

(2012) Paul R A Stokes et al.   NEUROPSYCHOPHARMACOLOGY

Dissociation of Hedonic Reaction to Reward and Incentive Motivation in an Animal Model of the Negative Symptoms of Schizophrenia

(2012) Ryan D Ward et al.   NEUROPSYCHOPHARMACOLOGY

Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia

(2012) Alice Egerton et al.   NEUROPSYCHOPHARMACOLOGY

Dopaminergic Neurotransmission in Patients with Schizophrenia in Relation to Positive and Negative Symptoms

(2012) O. Pogarell et al.   PHARMACOPSYCHIATRY

The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory

(2012) Euitae Kim et al.   PSYCHOPHARMACOLOGY

The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia

(2012) Diana C. Rotaru et al.   REVIEWS IN THE NEUROSCIENCES

Dopaminergic Function in the Psychosis Spectrum: An [18F]-DOPA Imaging Study in Healthy Individuals With Auditory Hallucinations

(2012) Oliver D. Howes et al.   SCHIZOPHRENIA BULLETIN

Neural and Behavioral Correlates of Aberrant Salience in Individuals at Risk for Psychosis

(2012) Jonathan P. Roiser et al.   SCHIZOPHRENIA BULLETIN

Transition to Psychosis Associated With Prefrontal and Subcortical Dysfunction in Ultra High-Risk Individuals

(2012) P. Allen et al.   SCHIZOPHRENIA BULLETIN

Dopamine Synthesis Capacity Before Onset of Psychosis: A Prospective [18F]-DOPA PET Imaging Study

(2011) Oliver D. Howes et al.   AMERICAN JOURNAL OF PSYCHIATRY

Imaging Changes in Glutamate Transmission In Vivo with the Metabotropic Glutamate Receptor 5 Tracer [11C] ABP688 and N-Acetylcysteine Challenge

(2011) Nobumi Miyake et al.   BIOLOGICAL PSYCHIATRY

Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia

(2011) Naoko Aoyama et al.   BRITISH JOURNAL OF PSYCHIATRY

Cost of disorders of the brain in Europe 2010

(2011) Anders Gustavsson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: a PET study with [11C]NNC112

(2011) Anissa Abi-Dargham et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study

(2011) O Howes et al.   MOLECULAR PSYCHIATRY

Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors

(2011) Graham M Pitcher et al.   NATURE MEDICINE

Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis

(2011) Camilo de la Fuente-Sandoval et al.   NEUROPSYCHOPHARMACOLOGY

Abnormal Activity of the MAPK- and cAMP-Associated Signaling Pathways in Frontal Cortical Areas in Postmortem Brain in Schizophrenia

(2011) Adam J Funk et al.   NEUROPSYCHOPHARMACOLOGY

In vivoandex vivoevidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia

(2011) Sang-Young Kim et al.   NMR IN BIOMEDICINE

Striatal dopamine synthesis capacity in twins discordant for schizophrenia

(2011) P. Shotbolt et al.   PSYCHOLOGICAL MEDICINE

Abnormal Relationship Between Medial Temporal Lobe and Subcortical Dopamine Function in People With an Ultra High Risk for Psychosis

(2011) P. Allen et al.   SCHIZOPHRENIA BULLETIN

Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies

(2011) Anouk Marsman et al.   SCHIZOPHRENIA BULLETIN

Striatal Dopamine Transporter Availability in Drug-Naive Patients With Schizophrenia: A Case-Control SPECT Study With [99mTc]-TRODAT-1 and a Meta-Analysis

(2011) K. C. Chen et al.   SCHIZOPHRENIA BULLETIN

Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans

(2011) Philip Seeman   SYNAPSE

Cognition in schizophrenia: core psychological and neural mechanisms

(2011) Deanna M. Barch et al.   TRENDS IN COGNITIVE SCIENCES

Abnormal Frontostriatal Interactions in People With Prodromal Signs of Psychosis

(2010) Paolo Fusar-Poli et al.   ARCHIVES OF GENERAL PSYCHIATRY

Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia

(2010) Lawrence S. Kegeles et al.   ARCHIVES OF GENERAL PSYCHIATRY

Altered Relationship Between Hippocampal Glutamate Levels and Striatal Dopamine Function in Subjects at Ultra High Risk of Psychosis

(2010) James M. Stone et al.   BIOLOGICAL PSYCHIATRY

Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis

(2010) Guochuan Tsai et al.   CURRENT PHARMACEUTICAL DESIGN

The Dopamine D1-D2 Receptor Heteromer Localizes in Dynorphin/Enkephalin Neurons

(2010) Melissa L. Perreault et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Imaging Cortical Dopamine D1 Receptors Using [11C]NNC112 and Ketanserin Blockade of the 5-HT2A Receptors

(2010) Ana M Catafau et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

The NADPH Oxidase NOX2 Controls Glutamate Release: A Novel Mechanism Involved in Psychosis-Like Ketamine Responses

(2010) S. Sorce et al.   JOURNAL OF NEUROSCIENCE

Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia

(2010) Jun Kosaka et al.   LIFE SCIENCES

A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia

(2010) Eleanor H. Simpson et al.   NEURON

Dopamine in Motivational Control: Rewarding, Aversive, and Alerting

(2010) Ethan S. Bromberg-Martin et al.   NEURON

Dopaminergic Dysfunction in Schizophrenia: Salience Attribution Revisited

(2010) A. Heinz et al.   SCHIZOPHRENIA BULLETIN

LY2140023 MONOHYDRATE: AN AGONIST AT THE MGLU2/3 RECEPTOR FOR THE TREATMENT OF SCHIZOPHRENIA

(2010) Bruce J. Kinon et al.   SCHIZOPHRENIA RESEARCH

Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization

(2010) Min Wang et al.   Molecular Brain

Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia

(2009) Oliver D. Howes et al.   ARCHIVES OF GENERAL PSYCHIATRY

Reward Feedback Alterations in Unmedicated Schizophrenia Patients: Relevance for Delusions

(2009) Florian Schlagenhauf et al.   BIOLOGICAL PSYCHIATRY

Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume

(2009) James M. Stone et al.   BIOLOGICAL PSYCHIATRY

Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects

(2009) Anissa Abi-Dargham et al.   BIOLOGICAL PSYCHIATRY

Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging

(2009) O. Howes et al.   CURRENT PHARMACEUTICAL DESIGN

A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia

(2009) Yechiel Levkovitz et al.   JOURNAL OF CLINICAL PSYCHIATRY

1H-MRS at 4 Tesla in minimally treated early schizophrenia

(2009) J R Bustillo et al.   MOLECULAR PSYCHIATRY

Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis

(2009) P Fusar-Poli et al.   MOLECULAR PSYCHIATRY

The test–retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function

(2009) Alice Egerton et al.   NEUROIMAGE

Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia

(2009) Adam J. Funk et al.   NEUROREPORT

PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches

(2009) Yoshitaka Kumakura et al.   NEUROSCIENTIST

Creatine abnormalities in schizophrenia and bipolar disorder

(2009) Dost Öngür et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

The effect of ageing on grey and white matter reductions in schizophrenia

(2009) Subrata K. Bose et al.   SCHIZOPHRENIA RESEARCH

Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: Investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus

(2009) So Young Yoo et al.   SCHIZOPHRENIA RESEARCH

Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: A 1H spectroscopy study

(2009) Matcheri S. Keshavan et al.   SCHIZOPHRENIA RESEARCH

The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis

(2009) Jari Tiihonen et al.   SCHIZOPHRENIA RESEARCH

Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3radiotracers [11C]FLB 457 and [11C]fallypride

(2009) Rajesh Narendran et al.   SYNAPSE

In vivo [123I]CNS-1261 binding to D-serine-activated and MK801-blocked NMDA receptors: A storage phosphor imaging study in rats

(2009) Remco J.J. Knol et al.   SYNAPSE

Further evaluation of the carbon11-labeled D2/3agonist PET radiotracer PHNO: Reproducibility in tracer characteristics and characterization of extrastriatal binding

(2009) Alice Egerton et al.   SYNAPSE

Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls

(2008) Celia J. A. Morgan et al.   ADDICTION

Glutamate and the Neural Basis of the Subjective Effects of Ketamine

(2008) J. F. William Deakin et al.   ARCHIVES OF GENERAL PSYCHIATRY

‘Truman’ signs and vulnerability to psychosis

(2008) Paolo Fusar-Poli et al.   BRITISH JOURNAL OF PSYCHIATRY

Minocycline as Adjunctive Therapy for Schizophrenia

(2008) Tsuyoshi Miyaoka et al.   CLINICAL NEUROPHARMACOLOGY

Proton MRS in twin pairs discordant for schizophrenia

(2008) E S Lutkenhoff et al.   MOLECULAR PSYCHIATRY

The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study

(2008) Ariel Graff-Guerrero et al.   NEUROPSYCHOPHARMACOLOGY

White Matter Alterations in Deficit Schizophrenia

(2008) Laura M Rowland et al.   NEUROPSYCHOPHARMACOLOGY

Do patients with schizophrenia exhibit aberrant salience?

(2008) J. P. Roiser et al.   PSYCHOLOGICAL MEDICINE

Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats

(2008) Alice Egerton et al.   PSYCHOPHARMACOLOGY

Psychiatric Comorbidities and Schizophrenia

(2008) P. F. Buckley et al.   SCHIZOPHRENIA BULLETIN

Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia

(2008) Scot E. Purdon et al.   SCHIZOPHRENIA RESEARCH

Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET

(2008) Shoko Nozaki et al.   SCHIZOPHRENIA RESEARCH

Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS)

(2008) Shin'Ya Tayoshi et al.   SCHIZOPHRENIA RESEARCH

Functional neuroimaging in schizophrenia: diagnosis and drug discovery

(2008) P MCGUIRE et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study

(2008) Hans M. Olbrich et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Striatal Dopamine Synthesis in First-degree Relatives of Patients with Schizophrenia

(2007) Jukka Huttunen et al.   BIOLOGICAL PSYCHIATRY

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline

(2007) Yuko Fujita et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY